Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter

Cancer Gene Therapy

Volumn 18, Issue 2, 2011, Pages 144-152

  Huang, R ^a   Zhao, Z ^a   Ma, X ^a   Li, S ^a   Gong, R ^a   Kuang, A ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

radioiodine therapy; sodium iodide symporter; survivin promoter

Indexed keywords

PERCHLORATE; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL STRAIN HEPG2; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TOOTH PULP; TUMOR GROWTH; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PROMOTER REGIONS, GENETIC; SYMPORTERS;

ADENOVIRIDAE;

EID: 78751625435     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.66     Document Type: Article

References (40)

1. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-460.
2. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80: 1083-1105.
3. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000; 10: 321-330.
4. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996; 226: 339-345.
5. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526-6530.
6. Willhauck MJ, Sharif Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ et al. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2007; 92: 4451-4458.
7. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 63: 7840-7844.
8. Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ et al. The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1272-1281.
9. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15: 214-223.
10. Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006; 47: 854-862.
11. Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN et al. Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther 2008; 19: 951-957.
12. Ma XJ, Huang R, Kuang AR. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest 2009; 27: 673-681.
13. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005; 90: 4457-4464.
14. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005; 12: 272-280.
15. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483-1489.
16. Schipper ML, Riese CG, Seitz S, Weber A, Behe M, Schurrat T et al. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo. Eur J Nucl Med Mol Imaging 2007; 34: 638-650.
17. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
18. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351: 882-883.
19. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61: 8664-8667.
20. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001; 98: 2091-2100.
21. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R et al. Expression of survivin in normal, hyperplas-tic, and neoplastic colonic mucosa. Hum Pathol 2001; 32: 119-125.
22. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
23. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-547.
24. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59: 3143-3151.
25. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344(Part 2): 305-311.
26. Huang R, Kuang A, Yu H, Ma C, Tang G. Construction of the recombinant adenovirus carrying sodium/iodide sympor-ter gene. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2005; 22: 765-768.
27. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S et al. Adenovirus-mediated transfer of the thyroid sodium/ iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
28. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 2002; 57: 559-574.
29. Mandell RB, Mandell LZ, Link Jr CJ. Radioisotope concentrator gene therapy using the sodium/iodide sympor-ter gene. Cancer Res 1999; 59: 661-668.
30. Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RJ. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1529-1536.
31. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154-158.
32. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522-528.
33. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11: 740-747.
34. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 2004; 11: 256-262. (Pubitemid 41184344)
35. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
36. Huang M, Batra RK, Kogai T, Lin YQ, Hershman JM, Lichtenstein A et al. Ectopic expression of the thyroperox-idase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612-618.
37. Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ et al. Effective cancer therapy with the alpha-particle emitter astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res 2006; 12: 1342-1348.
38. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
39. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93: 504-515.
40. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL et al. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 2006; 238: 42-52.